|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ch. 509 2007 Laws of Maryland
|
|
|
|
|
|
|
|
|
|
(1) provide a prescription drug benefit subsidy, as determined by the
Board, that may pay all or some of the deductibles, coinsurance payments, premiums,
and copayments under the federal Medicare Part D Pharmaceutical Assistance
Program for enrollees of the Program: and
(2) provide the subsidy to the maximum number of individuals eligible
for enrollment in the Program, subject to the moneys available in the segregated
account under § 14-504 of this subtitle.
(B) THE PROGRAM MAY LIMIT PAYMENT OF ANY SUBSIDY BY PAYING
THE SUBSIDY ONLY ON BEHALF OF ELIGIBLE INDIVIDUALS ENROLLED IN A
MEDICARE PART D PRESCRIPTION DRUG PLAN OR MEDICARE ADVANTAGE
PLAN THAT COORDINATES WITH THE PROGRAM IN ACCORDANCE WITH
FEDERAL REQUIREMENTS.
[(b)] (C) The Program may annually provide an additional subsidy, up to
the full amount of the Medicare Part D Prescription Drug Plan premium, for
individuals who qualify for a partial federal low-income subsidy.
[(c)] (D) The Program shall maintain a waiting list of individuals who meet
the eligibility requirements for the Program but who are not served bv the Program
due to funding limitations.
[(d)] (E) The Board shall determine annually:
(1) the number of individuals to be enrolled in the Program:
(2) the amount of subsidy to be provided under subsection (a) of this
section: and
(3) the amount of any additional subsidy provided under subsection
[(b)] (C) of this section.
[(e)] (F) On or before January 1 of each year, the Board, in accordance with
§ 2-1246 of the State Government Article, shall report to the General Assembly on:
(1) the number of individuals on the waiting list for the Program; and
(2) to the extent that the Board is able to collect the information;
(i) the number of enrollees with out-of-pocket prescription
drug costs that exceed $2,250, broken down for each fiscal quarter; and
|
|
|
|
|
|
|
|
|
|
(ii) the total annual out-of-pocket prescription drug costs for
enrollees.
- 3354 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
